C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $105.09M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.37
• Revenue Growth: 98.56%
• EPS Growth: 37.97%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 71,007,080
• 10 Day Avg. Volume: 1,670,355
• 30 Day Avg. Volume: 1,180,320
• PEG Ratio: -0.06
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.59
• Enterprise Value/Market Cap: 3.29
• Enterprise Value/Revenue: 2.50
• Enterprise Value/Gross Profit: 10.19
• Enterprise Value/Ebitda: -0.88
• 1Y Price Target: $3.50
• Price Target Upside: 136.49% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: $1.50 ▲(1.35%Upside)

The overall stock score of 43.4 reflects significant financial challenges, including persistent losses and negative cash flows, which weigh heavily on the financial performance score. Technical analysis shows bearish momentum, and valuation metrics are unfavorable with a negative P/E ratio. The high volatility indicated by the beta suggests further risk.

Positive Factors

Partnership Opportunities

Management intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.

Product Potential

CFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.

Valuation

The company's valuation at an EV of ~$50MM suggests a significant opportunity for growth, as the market currently assigns no value to certain promising programs.

Negative Factors

Market Competition

Competitors in the market could challenge the potential growth of CFT1946 and its ability to replace existing BRAF inhibitors.

Regulatory Uncertainty

The process of determining the dosing regimen for cemsi highlights challenges related to regulatory approval and competitive profiling.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

C4 Therapeutics generates revenue primarily through strategic collaborations and partnerships with other biotechnology and pharmaceutical companies. These agreements typically involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of TPD therapies. The company's partnerships often focus on leveraging its TORPEDO platform to advance novel drug candidates through various stages of clinical development. While C4 Therapeutics is actively engaged in research and development activities, its revenue model is heavily reliant on these collaborations to fund its operations and growth initiatives.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. The income statement reveals ongoing operational difficulties despite a modest revenue growth. The balance sheet is stable but highlights potential risks if financial performance does not improve. Cash flow issues, particularly negative operating and free cash flows, underscore inefficiencies in cash management.

Income Statement

The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.

Balance Sheet

The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.

Cash Flow

Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	39.78M	35.58M	20.76M	31.10M	45.78M	33.20M
Gross Profit	33.92M	35.58M	-96.95M	23.52M	42.88M	-44.27M
EBITDA	-99.67M	-103.37M	-122.10M	-124.28M	-78.84M	-62.89M
Net Income	-103.28M	-105.32M	-132.49M	-126.50M	-86.04M	-66.33M
Balance Sheet
Total Assets	319.52M	349.60M	376.45M	430.84M	506.76M	400.14M
Cash, Cash Equivalents and Short-Term Investments	215.09M	244.90M	253.68M	337.12M	309.28M	371.69M
Total Debt	64.37M	65.76M	70.98M	87.15M	42.88M	22.92M
Total Liabilities	124.38M	133.62M	130.34M	141.61M	117.16M	119.35M
Stockholders Equity	195.14M	215.99M	246.11M	289.23M	389.61M	280.79M
Cash Flow
Free Cash Flow	-80.50M	-65.34M	-108.55M	-111.44M	-88.24M	-67.90M
Operating Cash Flow	-80.32M	-65.16M	-106.84M	-105.94M	-86.97M	-67.25M
Investing Cash Flow	31.25M	-51.27M	158.35M	58.42M	-189.34M	-190.50M
Financing Cash Flow	10.71M	45.34M	45.49M	1.15M	171.40M	348.93M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.48
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Negative. The current price of 1.48 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.50, and below the 200-day MA of 3.30, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.83 is Neutral, neither overbought nor oversold. The STOCH value of 53.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
ZNTL	46 Neutral	$90.66M	―	-59.45%	―	―	48.92%
CCCC	43 Neutral	$105.09M	―	-45.55%	―	98.56%	37.97%
ZURA	43 Neutral	$69.92M	―	-62.34%	―	―	86.65%
CLYM	41 Neutral	$86.50M	―	-62.04%	―	―	-61.95%
KYTX	36 Underperform	$121.45M	―	-49.72%	―	―	―
VOR	33 Underperform	$238.67M	―	-125.43%	―	―	2.98%

C4 Therapeutics Corporate Events

C4 Therapeutics Holds Annual Stockholders Meeting

On June 18, 2025, C4 Therapeutics held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and operational strategies. Stockholders elected three Class II directors, approved executive compensation, ratified KPMG LLP as the independent auditor, and agreed to amend the company’s certificate of incorporation to double the authorized shares of common stock, reflecting strategic growth ambitions.

The most recent analyst rating on (CCCC) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Updates on Cemsidomide Clinical Trial

On May 7, 2025, C4 Therapeutics announced updates from its Phase 1 clinical trial of cemsidomide, a small-molecule degrader for multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL). The trial’s dose escalation phase in MM is complete, with the 100 µg QD dose level showing a 50% overall response rate, including a complete response in one patient. The trial continues for NHL, with the maximum tolerated dose not yet reached. C4T plans to prioritize cemsidomide’s development and expects regulatory feedback by mid-2025 to support further clinical development in 2026. Financially, C4T reported a net loss of $26.3 million for Q1 2025, with cash reserves expected to fund operations into 2027.

C4 Therapeutics Board Member Bruce Downey Retires

On April 10, 2025, Bruce Downey announced his retirement from the Board of Directors of C4 Therapeutics and will not stand for reelection at the 2025 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company’s strategy or operations, and he will step down from various committee roles following the meeting.